Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.

Wolfgang Kamin, Lidia I Ilyenko, Fathi A Malek, Meinhard Kieser

RCT Pediatrics international : official journal of the Japan Pediatric Society 2012 56 citations

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'pmid\u003D22360575'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

Study Type: Randomized Controlled Trial
Sample Size: 220
Population: Children and adolescents with acute bronchitis
Duration: 1 weeks

Intervention: Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents. 3x10-30 drops/day (age-adjusted)
Comparator: Placebo drops
Primary Outcome: Bronchitis Severity Score (BSS) change
Effect Direction: Positive
Risk of Bias: Low

Abstract

BACKGROUND: The aim of this trial was to investigate the efficacy and tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides, in children and adolescents suffering from acute bronchitis, outside the strict indication for antibiotics. METHODS: A total of 220 patients with acute bronchitis were randomized and given either verum containing EPs 7630 (1-6 years/>6-12 years/>12-18 years: 3 × 10/3 × 20/3 × 30 drops/day) or matching placebo for 7 days. The main outcome measure was the change in the total score of bronchitis-specific symptoms (BSS) from day 0 to day 7. RESULTS: The decrease in the BSS total score was significantly higher for EPs 7630 compared to placebo (change day 0-day 7: 4.4 ± 1.6 vs 2.9 ± 1.4 points; P < 0.0001). Improvements were most pronounced for 'coughing' and 'rales at auscultation'. Tolerability was similarly good in both groups. CONCLUSIONS: EPs 7630 proved to be an efficacious and well-tolerated option for the treatment of acute bronchitis in children and adolescents outside the strict indication for antibiotics.

TL;DR

The aim of this trial was to investigate the efficacy and tolerability of EPs 7630, a herbal drug preparation from Pelargonium sidoides, in children and adolescents suffering from acute bronchitis outside the strict indication for antibiotics.

Used In Evidence Reviews

A Pelargonium sidoides for Acute Bronchitis

Treatment of acute bronchitis with EPs 7630: randomized, controlled trial in children and adolescents.

Embed This Widget

Study Design

Abstract

TL;DR

Used In Evidence Reviews

Similar Papers

A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae).

Investigation of the influence of EPs® 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses.

Pelargonium sidoides extract for treating acute respiratory tract infections.

EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo.

Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial.

Pelargonium sidoides for acute bronchitis: a systematic review and meta-analysis.